Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsReiterationPrice Target
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.
Citizens analyst Jonathan Wolleben reiterates Biomea Fusion (NASDAQ:BMEA) with a Market Outperform and maintains $7 price target.